Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis
暂无分享,去创建一个
D. Dalela | J. Peabody | A. Sood | C. Rogers | I. Rakić | M. Butaney | F. Abdollah | S. Majdalany | M. Jamil | N. Corsi | A. Stephens | Emily Chan Brodowsky | Alex Stephens | A. Piontkowski | E. Brodowsky | Austin J. Piontkowski
[1] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[2] H. Weir,et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.
[3] R. Fisher,et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. , 2020, The Lancet Oncology.
[4] L. Sumoy,et al. PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate , 2020, Cancer management and research.
[5] H. G. van der Poel,et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.
[6] C. Roehrborn,et al. Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution study , 2018, BJU international.
[7] J. Aragon-Ching,et al. Role of chemotherapy in prostate cancer , 2017, Asian journal of andrology.
[8] D. Grignon,et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.
[9] D. Mazhar,et al. The evolving role of chemotherapy in prostate cancer. , 2017, Future oncology.
[10] L. Salomon,et al. Conditional Disease-free Survival After Radical Prostatectomy: Recurrence Risk Evolution Over Time. , 2016, Urology.
[11] W. Jackson,et al. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.
[12] D. Curran‐Everett,et al. Post-hoc data analysis: benefits and limitations. , 2013, Current opinion in allergy and clinical immunology.
[13] Anthony V D'Amico,et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.
[14] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[15] F. Thuillier,et al. [PSA kinetics after radiotherapy]. , 2009, Annales de Biologie Clinique.